Last reviewed · How we verify
NCT05259072: DISSOLvE
carDIo-ttranSSfOrm nucLEar Imaging Study
trial testing 99m-technetium pyrophosphate scintigraphy in Amyloidosis in 4 participants. Terminated before completion.
30 December 2023
Quick facts
| Lead sponsor | Oregon Health and Science University |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 4 |
| Start date | 19 January 2022 |
| Primary completion | 30 December 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 99m-technetium pyrophosphate scintigraphy
Conditions studied
- Amyloidosis — all drugs for Amyloidosis →
- Transthyretin Amyloid Cardiomyopathy — all drugs for Transthyretin Amyloid Cardiomyopathy →
Sponsor
Oregon Health and Science University
Who can join
Adults 60 to 90, any sex, with Amyloidosis or Transthyretin Amyloid Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators will evaluate the change in myocardial uptake of 99m-technetium pyrophosphate (Tc-99m PYP) tracer on serial planar and SPECT imaging in patients enrolled in the CARDIO-TTRansform clinical trial (NCT04136171).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Hepatocyte targeting <i>via</i> the asialoglycoprotein receptor.
Ramírez-Cortés F, Ménová P. · · 2025 · cited 22× · PMID 39628900 · DOI 10.1039/d4md00652f
Verify or expand the search:
- PubMed search for NCT05259072
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Amyloidosis
Currently open trials in the same condition.
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT06974877 — Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure · Phase 1 · recruiting
- NCT07081646 — A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloido · Phase 1, PHASE2 · recruiting
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
Other Oregon Health and Science University trials
Trials by the same sponsor.
- NCT07431970 — Assessing Construction Execution Under Sleep Impairment · NA · not yet recruiting
- NCT07309757 — Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD) · not yet recruiting
- NCT07282639 — App-Based Certified Diabetes Education Therapy (AB-CDE) · NA · not yet recruiting
- NCT07322588 — Reentry Incentives and Support for Engagement With Contingency Management · NA · not yet recruiting
- NCT07220590 — Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05259072 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oregon Health and Science University
- Last refreshed: 29 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05259072.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing